PE106300A1 - Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa - Google Patents

Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa

Info

Publication number
PE106300A1
PE106300A1 PE1998000776A PE00077698A PE106300A1 PE 106300 A1 PE106300 A1 PE 106300A1 PE 1998000776 A PE1998000776 A PE 1998000776A PE 00077698 A PE00077698 A PE 00077698A PE 106300 A1 PE106300 A1 PE 106300A1
Authority
PE
Peru
Prior art keywords
alkynyl
alkyl
compound
imidazoquinoxalins
inhibitors
Prior art date
Application number
PE1998000776A
Other languages
English (en)
Inventor
Jagabandhu Das
Edwin J Iwanowicz
Derek J Norris
Joel C Barrish
Jacques Y Roberge
Gary L Schieven
Ping Chen
Ramesh Padmanabha
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE106300A1 publication Critical patent/PE106300A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA IMIDAZOQUINOXALINA DE FORMULA I DONDE p ES 0-4; R1, R2 Y R3 SON H, R6, OH, OR6, SH, SR6, C(O)qH, -OC(O)qR6, SO3H, HALO, CIANO, ENTRE OTROS; q ES 1 o 2; R6 ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R4 Y R5 SON H, R6 o -C(O)R6 o JUNTO CON N FORMAN UN ANILLO DE 3-8 MIEMBROS, OPCIONALMENTE SUSTITUIDO POR Z1, Z2 Y Z3; R7, R8, R9, R10, R11 Y R12 SON H, R6, O R7 Y R8 O R9, R10 Y R11 SON ALQUILENO O ALQUENILENO FORMANDO PARTE DE UN ANILLO DE 3-8 MIEMBROS; R13, R14 Y R15 SON ALQUILO O FENILO; Z1, Z2, Z3 SON H, Z6, OH, OZ6, SH, SZ6, C(O)qH, -OC(O)qZ6, ENTRE OTROS; Z6 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES N-(2-CLORO-6-METILFENIL)-8-NITROIMIDAZO[1,5-a]-QUINOXALIN-4-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. TAMBIEN JUNTO AL COMPUESTO I SE UTILIZA UN ANTIINFLAMATORIO, ANTIPROLIFERATIVO, INMUNOSUPRESOR. EL COMPUESTO I PUEDE SER UTIL PARA TRATAR UN PADECIMIENTO O DESORDEN ASOCIADO CON LA PROTEINA TIROSINA CINASA COMO RECHAZO DE TRANSPLANTE, ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE, LUPUS, INJERTO, HIPERSENSIBILIDAD MEDIADA POR LAS CELULAS T, PSORIASIS, TIROIDITIS DE HASHIMOTO, SINDROME DE GUILLEN-BARRE, DERMATITIS, ASMA, CANCER
PE1998000776A 1997-08-25 1998-08-25 Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa PE106300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5677097P 1997-08-25 1997-08-25
US6915997P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
PE106300A1 true PE106300A1 (es) 2000-01-23

Family

ID=26735691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000776A PE106300A1 (es) 1997-08-25 1998-08-25 Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa

Country Status (5)

Country Link
US (1) US6235740B1 (es)
AR (1) AR013441A1 (es)
AU (1) AU8681798A (es)
PE (1) PE106300A1 (es)
WO (1) WO1999009845A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322311C (en) * 1998-03-04 2009-10-13 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US20060258686A1 (en) * 1998-05-29 2006-11-16 Cheresh David A Method of treatment of myocardial infarction
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
EP1206260A4 (en) 1999-06-30 2002-10-30 Merck & Co Inc SRC-KINASE INHIBITING COMPOUNDS
CA2376951A1 (en) 1999-06-30 2001-01-04 Peter J. Sinclair Src kinase inhibitor compounds
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US20030176454A1 (en) * 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
ES2260300T3 (es) * 2000-10-03 2006-11-01 Bristol-Myers Squibb Company Compuestos tetraciclicos sustituidos con amino utiles como agentes antiinflamatorios y composiciones farmaceuticas que comprenden los mismos.
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
CZ20032287A3 (cs) * 2001-02-01 2004-02-18 Bristol-Myers Squibb Company Způsoby léčení zánětlivých a imunitních nemocí za použití inhibitorů IkB kinázy (IKK)
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
US6821988B2 (en) * 2001-11-27 2004-11-23 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
US20040180898A1 (en) * 2003-03-03 2004-09-16 Bang-Chi Chen Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
US7880017B2 (en) * 2003-11-11 2011-02-01 Allergan, Inc. Process for the synthesis of imidazoles
US7183305B2 (en) * 2003-11-11 2007-02-27 Allergan, Inc. Process for the synthesis of imidazoles
US20060025419A1 (en) * 2004-06-25 2006-02-02 Ann Richmond Imidazoquinoxaline compound for the treatment of melanoma
US8003657B2 (en) * 2004-10-13 2011-08-23 Merck Patent Gmbh Heterocyclic substituted bisarylurea derivatives
WO2007106884A2 (en) 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US20080076770A1 (en) * 2006-09-25 2008-03-27 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
CN101616919B (zh) * 2006-12-28 2012-10-10 雅培制药有限公司 聚（adp核糖）聚合酶抑制剂
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
CA2706866A1 (en) * 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
EP2227472A1 (en) * 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
WO2010025073A1 (en) * 2008-08-28 2010-03-04 Takeda Pharmaceutical Company Limited Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
CN102341399A (zh) 2009-03-05 2012-02-01 安斯泰来制药株式会社 喹喔啉化合物
US8361962B2 (en) * 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
KR101481872B1 (ko) * 2009-09-10 2015-01-12 에프. 호프만-라 로슈 아게 Ｊａｋ의 억제제
CN102498113B (zh) * 2009-09-21 2014-11-26 弗·哈夫曼-拉罗切有限公司 Jak的大环抑制剂
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AU2011299936A1 (en) 2010-09-07 2013-03-28 Astellas Pharma Inc. Quinoxaline compound
US9540379B2 (en) * 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
WO2024027370A1 (zh) * 2022-08-03 2024-02-08 上海和誉生物医药科技有限公司 一种含氮三稠环prmt5抑制剂，其制备方法和药学上的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229452A (en) 1977-01-07 1980-10-21 Westwood Pharmaceuticals, Inc. Treatment of inflammatory disorders with 4-trifluoromethylimidazo[1,2-a]quinoxaline
US4236015A (en) 1977-01-07 1980-11-25 Westwood Pharmaceuticals, Inc. 1-(2-Acylaminophenyl)imidazoles
US4225724A (en) 1977-01-07 1980-09-30 Westwood Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US4197403A (en) 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4191766A (en) 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for reducing immunological response
US4198508A (en) 1977-01-07 1980-04-15 Westwood Pharmaceuticals Inc. Process for preparing 4-substituted imidazo[1,2-a]quinoxalines
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US4172947A (en) 1977-01-07 1979-10-30 Westwood Pharmaceuticals, Inc. 1-(2-Acylaminophenyl)imidazoles
US4191767A (en) 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4160097A (en) 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
JPS5632549A (en) 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
US4440929A (en) 1981-07-16 1984-04-03 Usv Pharmaceutical Corporation Imidazoquinoxaline compounds
DK161148C (da) 1988-06-14 1991-11-18 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til fremstilling deraf samt farmaceutiske praeprater indeholdende forbindelserne
DK151890D0 (da) * 1990-06-22 1990-06-22 Ferrosan As Heterocykliske forbindelser deres fremstilling og brug
US5276028A (en) 1990-06-22 1994-01-04 Nordisk A/S Imidazoquinoxaline compounds
DE19506742A1 (de) 1995-02-27 1996-08-29 Bayer Ag Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
IT1276167B1 (it) 1995-11-24 1997-10-27 Foscama Biomed Chim Farma Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni

Also Published As

Publication number Publication date
WO1999009845A1 (en) 1999-03-04
US6235740B1 (en) 2001-05-22
AU8681798A (en) 1999-03-16
AR013441A1 (es) 2000-12-27

Similar Documents

Publication Publication Date Title
PE106300A1 (es) Imidazoquinoxalinas como inhibidores de la proteina tirosina cinasa
PE129799A1 (es) Inhibidores de benzotiazol de la proteina tirosina cinasa
MX9304646A (es) Nuevas 7-(sustituido)-8-(sustituido)d-9-[(glicilo sustituido)amido]-6-desmetil-6-desoxitetraciclinasy metodo para su produccion.
AU6691094A (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
MX9304647A (es) 7-(sustituido)-9-[(glicilo sustituido)amido]-6-desmetil-6-desoxitetraciclinas y metodo para su produccion.
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
AU584663B2 (en) Thieno-triazolo-1,4-diazepino-2-carboxylic acid amides
MX9302214A (es) Derivados de taxol y proceso para su preparacion
ES2190440T3 (es) Compuestos antitumorales, composiciones farmaceuticas, modos de preparacion y para el tratamiento.
NO932872L (no) Nye 7-(substituerte)-8-(substituerte)-9-(substituert amino)-6-demetyl-6-deoksy-tetracykliner
BR9906905A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para a preparação de um composto, para tratamento e/ou prevenção de ansiedade e para o tratamento e/ou prevenção de convulsões.
MX9302169A (es) Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales.
NZ330244A (en) Isoxazole derivatives useful in the treatment of inflammatory diseases
AU554959B2 (en) Triazolo(4,3-a) quinazolin-5-ones
AU4844290A (en) Halo substituted aminotetralins
ATE174327T1 (de) Bicyclo (2.2.2) oktan-derivate mit cholecystokinin und/oder gastrin antagonistischer wirkung
PT93126A (pt) Processo para a preparacao de eteres carboxialquilicos da 2-amino-7- -hidroxitetralina
ES2074508T3 (es) Benzocicloalquilaminopiridinaminas y compuestos afines, un procedimiento e intermediarios para su preparacion y su uso como medicamentos.
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
NZ333229A (es)
SE8304545D0 (sv) Benzamide derivatives
ATE216233T1 (de) Indolditerpen alkaloide
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
ES2074618T3 (es) 3-(1h-indazol-3-il)-4-piridinaminas, un procedimiento e intermediarios para su preparacion y su uso como medicamentos.
PT1019347E (pt) Metodo para a sintese de taxanos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal